CN113710671A - 作为布鲁顿酪氨酸激酶抑制剂的环状分子 - Google Patents

作为布鲁顿酪氨酸激酶抑制剂的环状分子 Download PDF

Info

Publication number
CN113710671A
CN113710671A CN202080009961.2A CN202080009961A CN113710671A CN 113710671 A CN113710671 A CN 113710671A CN 202080009961 A CN202080009961 A CN 202080009961A CN 113710671 A CN113710671 A CN 113710671A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
pyrimidin
group
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080009961.2A
Other languages
English (en)
Other versions
CN113710671B (zh
Inventor
王召印
姚兵
姚元山
李傲
曹国庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minghui Pharmaceutical Hangzhou Co ltd
Minghui Pharmaceutical Shanghai Co ltd
Original Assignee
Minghui Pharmaceutical Hangzhou Co ltd
Minghui Pharmaceutical Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minghui Pharmaceutical Hangzhou Co ltd, Minghui Pharmaceutical Shanghai Co ltd filed Critical Minghui Pharmaceutical Hangzhou Co ltd
Priority to CN202310355998.6A priority Critical patent/CN116589465A/zh
Publication of CN113710671A publication Critical patent/CN113710671A/zh
Application granted granted Critical
Publication of CN113710671B publication Critical patent/CN113710671B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明描述了具有蛋白酶氨酸激酶抑制活性的新型分子，以及该化合物的合成和使用方法。具体地，本发明描述了式(A)化合物或其药学上可接受的盐、水合物或溶剂合物，以及该化合物的合成和使用方法。
Figure DDA0003170035450000011

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080009961.2A 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子 Active CN113710671B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310355998.6A CN116589465A (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100491839 2019-01-18
CN201910049183.9A CN111454268B (zh) 2019-01-18 2019-01-18 作为布鲁顿酪氨酸激酶抑制剂的环状分子
PCT/CN2020/072551 WO2020147798A1 (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310355998.6A Division CN116589465A (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子

Publications (2)

Publication Number Publication Date
CN113710671A true CN113710671A (zh) 2021-11-26
CN113710671B CN113710671B (zh) 2023-04-28

Family

ID=71613532

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910049183.9A Active CN111454268B (zh) 2019-01-18 2019-01-18 作为布鲁顿酪氨酸激酶抑制剂的环状分子
CN202310355998.6A Pending CN116589465A (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子
CN202080009961.2A Active CN113710671B (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201910049183.9A Active CN111454268B (zh) 2019-01-18 2019-01-18 作为布鲁顿酪氨酸激酶抑制剂的环状分子
CN202310355998.6A Pending CN116589465A (zh) 2019-01-18 2020-01-16 作为布鲁顿酪氨酸激酶抑制剂的环状分子

Country Status (13)

Country Link
US (1) US20220081445A1 (zh)
EP (1) EP3912980A4 (zh)
JP (2) JP7436994B2 (zh)
KR (1) KR20210135497A (zh)
CN (3) CN111454268B (zh)
AU (1) AU2020208128B2 (zh)
BR (1) BR112021014100A2 (zh)
CA (1) CA3129841C (zh)
EA (1) EA202191995A1 (zh)
IL (1) IL284916A (zh)
MX (1) MX2021008632A (zh)
SG (1) SG11202107886RA (zh)
WO (1) WO2020147798A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510212A (ja) * 2020-01-02 2023-03-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｂｔｋ阻害薬
CN113943294A (zh) * 2020-07-15 2022-01-18 成都海博为药业有限公司 一种作为btk抑制剂的化合物及其制备方法与用途
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520298A (zh) * 2001-03-22 2004-08-11 �����ʩ���عɷݹ�˾ 作为治疗剂的吡唑并嘧啶类
CN101610676A (zh) * 2006-09-22 2009-12-23 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CN102656173A (zh) * 2009-10-12 2012-09-05 药品循环公司 布鲁顿酪氨酸激酶抑制剂
CN105732638A (zh) * 2016-01-22 2016-07-06 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
CN107827892A (zh) * 2017-10-27 2018-03-23 上海应用技术大学 一种非受体酪氨酸激酶小分子抑制剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002936A3 (cs) * 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
EP1730148A4 (en) 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
JP2009520028A (ja) 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
JP5369183B2 (ja) * 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP6114296B2 (ja) 2011-11-08 2017-04-12 インテリカイン， エルエルシー 複数の医薬品を使用した治療レジメン
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
CA2874211A1 (en) 2012-05-31 2013-12-05 Pharmascience Inc. Protein kinase inhibitors
KR102150432B1 (ko) 2012-06-18 2020-09-01 프린시피아 바이오파마, 인코퍼레이티드 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘
NZ721617A (en) * 2014-02-03 2018-01-26 Cadila Healthcare Ltd Heterocyclic compounds
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016004305A2 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
TW201613926A (en) * 2014-08-01 2016-04-16 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AU2015296215A1 (en) * 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP7337502B2 (ja) 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018009017A1 (en) * 2016-07-07 2018-01-11 Daewoong Pharmaceutical Co., Ltd. NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2018089786A1 (en) 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1520298A (zh) * 2001-03-22 2004-08-11 �����ʩ���عɷݹ�˾ 作为治疗剂的吡唑并嘧啶类
CN101610676A (zh) * 2006-09-22 2009-12-23 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CN102656173A (zh) * 2009-10-12 2012-09-05 药品循环公司 布鲁顿酪氨酸激酶抑制剂
CN105732638A (zh) * 2016-01-22 2016-07-06 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
CN107827892A (zh) * 2017-10-27 2018-03-23 上海应用技术大学 一种非受体酪氨酸激酶小分子抑制剂及其应用

Also Published As

Publication number Publication date
CN116589465A (zh) 2023-08-15
BR112021014100A2 (pt) 2021-09-21
AU2020208128A1 (en) 2021-09-09
JP2023179562A (ja) 2023-12-19
WO2020147798A1 (zh) 2020-07-23
MX2021008632A (es) 2021-10-26
AU2020208128B2 (en) 2023-05-25
JP2022523480A (ja) 2022-04-25
SG11202107886RA (en) 2021-08-30
EA202191995A1 (ru) 2021-11-18
CA3129841C (en) 2023-09-26
KR20210135497A (ko) 2021-11-15
IL284916A (en) 2021-09-30
JP7436994B2 (ja) 2024-02-22
EP3912980A4 (en) 2022-12-07
US20220081445A1 (en) 2022-03-17
EP3912980A1 (en) 2021-11-24
CN111454268B (zh) 2023-09-08
CA3129841A1 (en) 2020-07-23
CN111454268A (zh) 2020-07-28
CN113710671B (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
EP2809673B1 (en) Spirocyclic molecules as bruton's tyrosine kinase inhibitors
US9193721B2 (en) Fused derivatives as PI3Kδ inhibitors
AU2021200839A1 (en) Pyrazole pyrimidine derivative and uses thereof
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
JP2023162216A (ja) Ｐｄ－ｌ１免疫調節剤としてのテトラヒドロ－イミダゾ［４，５－ｃ］ピリジン誘導体
US11987584B2 (en) Heterobicyclic amides as inhibitors of CD38
CN105228997A (zh) Carm1抑制剂及其用途
CN113710671B (zh) 作为布鲁顿酪氨酸激酶抑制剂的环状分子
TW200820972A (en) 4-methylpyridopyrimidinone compounds
WO2013185202A1 (en) Apoptosis inducers
US9226923B2 (en) Spirocyclic molecules as protein kinase inhibitors
US8946445B2 (en) Heterocyclic molecules as apoptosis inducers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056349

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant